Upcoming Events

Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.

Archived Events
Date Event Details
Aug 16, 2017
9:10 AM
2017 Wedbush PacGrow Healthcare Conference
Aug 2, 2017
4:30 PM ET
MacroGenics, Inc. Second Quarter 2017 Financial Results Conference Call
Jun 17, 2017
MacroGenics Presentation at the Annual European Congress of Rheumatology (EULAR 2016)
Jun 5, 2017
9:00 AM ET
Trials-in-Progress Poster Presentation at ASCO Annual Meeting 2017
May 16, 2017
4:00 PM ET
MacroGenics Presentation at the Bank of America Merrill Lynch 2017 Healthcare Conference
May 3, 2017
4:30 PM ET
MacroGenics, Inc. First Quarter 2017 Financial Results Conference Call
May 3, 2017
1:30 PM ET
MacroGenics Presentation at the Deutsche Bank 42nd Annual Health Care Conference
Apr 2–4, 2017
1:00 PM ET
Presentation of eight posters at 2017 AACR Annual Meeting
  • Preclinical Development of a Duocarmycin-Based ADC Targeting B7-H3 for Solid Cancer
  • Target Validation, Antibody Discovery and Preclinical Data Supporting ADAM9 as ADC
  • Novel ADC Targeting ADAM9-expressing Solid Tumors Demonstrate Potent Preclin. Activity 
  • Tumor-Antigen Expression-Dependent Activ. of CD137 Costim. Pathway by DART Proteins 
  • Co-targeting PD-1 and CTLA-4 Inhibitory Pathways with DART and TRIDENT Molecules 
  • Potent Antitumor Activity of Duvortuxizumab (CD19 x CD3 DART) in Lymphoma Models 
  • Quant. Prediction of Human PK for Duvortuxizumab: a Translational PK Model. Approach 
  • 5T4 x CD3 DART Molecule w/ Extended Half-life for T-cell Immunotherapy of Cancers 
Feb 28, 2017
4:30 PM ET
MacroGenics, Inc. Fourth Quarter and Full Year 2016 Financial Results Conference Call
Jan 20, 2017
Margetuximab TIP Poster Presentation at 2017 ASCO Gastrointestinal Cancers Symposium
Dec 13, 2016
8:30 AM ET
MacroGenics, Inc. R&D Day 2016
Dec 7, 2016
Margetuximab TIP Poster Presentation at San Antonio Breast Cancer Symposium 2016
Jun 10, 2016
5:40 AM ET
MacroGenics Presentation at the Annual European Congress of Rheumatology (EULAR 2016)
Jun 5, 2016
9:00 AM ET
Trials-in-Progress Poster Presentation at ASCO Annual Meeting 2016
Apr 17–19, 2016
2:00 PM ET
Five Posters Presented at 2016 American Association for Cancer Research (AACR) Annual Meeting
Mar 7, 2016
Preclinical Data Presented at Keystone Symposia's Antibodies as Drugs (X2) Conference: MGD009, a B7-H3 x CD3 Bispecific Dual-Affinity Re-Targeting (DART®) Molecule Directing T Cells to Solid Tumors
Nov 7, 2015
12:00 PM ET
Data presented at SITC Annual Meeting 2015: Interim Results of an Ongoing Phase 1, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3
May 30, 2015
8:00 AM - 11:30 AM CT
Data Presented at ASCO Annual Meeting 2015:
Updated findings of a first-in-human phase 1 study of margetuximab, an Fc-optimized chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors

Location: S Hall A
Poster Board Number: 11
Abstract Number: 523
Presented by: Howard A. Burris, M.D.

Apr 20, 2015
1:00 PM - 5:00 PM ET
Preclincal Data Presented at AACR Annual Meeting 2015:
DART® molecules with enhanced DR5 agonistic activity for improved cancer cell cytotoxicity

Location: Poster section 25
Poster Board Number: 6
Abstract Number: 2464
Presented by: MacroGenics, Inc

Dec 6, 2014
5:30 PM ET
Preclinical Data Presented at ASH 2014 Annual Meeting:
MGD011, a Humanized CD19 x CD3 DART® Protein with Enhanced Pharmacokinetic Properties, Demonstrates Potent T-cell Mediated Anti-Tumor Activity in Preclinical Models and Durable B-cell Depletion in Cynomolgus Monkeys Following Once-a-Week

Presenter: Liqin Liu, Ph.D., Senior Scientist at MacroGenics
Session Name: 625. Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents: Poster I
Presentation Date and Time: Saturday, December 6, 2014; 5:30 PM - 7:30 PM PT
Location: West Building, Level 1 (Moscone Center)
Abstract Number: 1775

Nov 19, 2014
Poster presentation at 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain:
Preclinical Activity and Safety of MGD006/S80880, a CD123 x CD3 Bispecific DART® Molecule for the Treatment of Hematological Malignancies
  •          View MGD006 EORTC-NCI-AACR Poster
Nov 6, 2014
10:00 AM ET
Trials-in-progress posters presented at the 29th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD:
  • MGD006  - A Phase 1 trial of MGD006 in patients with relapsed acute myeloid leukemia (AML)
  • MGD007  - A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Relapsed/Refractory Metastatic Colorectal Carcinoma
May 5, 2014
2:30 PM ET
MacroGenics to Present Pre-Clinical Data on Novel DART Candidate MGD010 for Autoimmune Disorders at IMMUNOLOGY 2014
Apr 6, 2014
4:00 PM ET
AACR Poster Presentation: Development of MGD007, a gpA33 x CD3 bi-specific DART for T-cell immunotherapy of metastatic colorectal cancer
Location: 1:00-5:00pm PDT in Hall A-E, poster section 28, poster number 26
Dec 9, 2013
11:45 AM CT
ASH Oral Presentation:
Targeting CD123 In Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecules (DARTs)
Speaker: Muneera H. Al-Hussaini, M.D., an investigator from the Division of Hematology & Oncology, Washington University School of Medicine in St. Louis
Location: La Nouvelle Ballroom C (Ernest N. Morial Convention Center)

The team investigated the ability of a DART constructed from an antibody to CD123 (7G3) and a MacroGenics' proprietary CD3 antibody, MGD006, to redirect T cells against CD123+ AML blasts. 

Click here for more information.

= add file to Briefcase

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close